At Aniling, we are committed to bringing advances in the Genomics arena to everyday health care and disease prevention. We aim to accelerate epigenomics to help make precision medicine a reality. Aniling has patented the GEUS technology (Genomic and Epigenomic Unified Sequencing), which allows for the first time simultaneous and high-reliability analysis of genome and epigenome, and provides end-to-end solutions for the right treatment decisions in oncology.

Our company is a spin-off of the Institute of Predictive and Personalized Medicine of Cancer (IMPPC), currently integrated in the Germans Trias i Pujol Biomedical Research Institute (IGTP). Aniling has offices and laboratories in the IGTP and full access to shared resources and facilities of the Can Ruti Campus, which includes the Hospital Germans Trias i Pujol, the Autonomous University of Barcelona and five biomedical research institutes (IGTP, IRSICaixa, IJC, Guttmann Institute and ICO).